Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 25, Issue 5, pp 352–354 | Cite as

Relationship between the pharmacokinetics and toxicity of mitozolomide

  • D. J. Kerr
  • J. A. Slack
  • P. Secrett
  • M. F. G. Stevens
  • G. R. P. Blackledge
  • C. Bradley
  • S. B. Kaye
Original Articles Pharmacokinetics, Toxicity, Mitozolomide

Summary

The cytotoxic drug mitozolomide has been found to cause unpredictably severe thrombocytopenia during phase I and II clinical trials. In an attempt to relate dose and pharmacokinetic parameters to toxicity, we measured plasma concentrations of mitozolomide in 14 patients with a range of malignancies. There were significant correlations (Spearman rank correlation test) between drug clearance and AUC and white blood cell nadir. The pharmacokinetic and toxicity data were not normally distributed; therefore, it was not possible to construct predictive nomograms for toxicity based on linear regression analysis.

Keywords

Plasma Concentration Thrombocytopenia White Blood Cell Linear Regression Analysis Rank Correlation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction ofcis-diamine (1,1-cyclobutane dicarboxylate) platinum in patients with impaired renal function. Cancer Res 44:5432Google Scholar
  2. 2.
    Fodstad O, Aamdal S, Pipl A, Boyd MR (1985) Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas and lung and colon carcinomas. Cancer Res 45:1778Google Scholar
  3. 3.
    Goldberg JA, Kerr DJ, Willmott N, McKillop JH, McArdle CS (1988) Pharmacokinetics and pharmacodynamics of loco regional S-fluorouracil in advanced colorectal metastases. Br J Cancer 57:186–198Google Scholar
  4. 4.
    Harding M, Northcott D, Smyth J, Stuart NSA, Green JA, Newlands E (1988) Short communication: phase II evaluation of mitozolomide in ovarian cancer. Br J Cancer 57:113Google Scholar
  5. 5.
    Joss RA, Ryssel HJ, Bischoff AK, Goldhirsch A, Brunner KW (1986) Abbreviated phase I clinical trial of IV mitozolomide. Cancer Treat Rep 70(6):797Google Scholar
  6. 6.
    Newell DR, Calbert AH, O'Reilly S, Burnell M, Gumbrell LA, Oxall FE, Gore ME, Wiltshaw E (1987) Prospective validation of a simple formula for determining carboplatin dosage. Br J Cancer 56:233Google Scholar
  7. 7.
    Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L, Stevens MFG (1985) Phase I clinical trial of mitozolomide. Cancer Treat Rep 69(7):801Google Scholar
  8. 8.
    Powis G (1985) Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14:177Google Scholar
  9. 9.
    Slack JA, Goddard C (1985) Antitumour imidazotetrazines: VII. Quantitative analysis of mitozolomide in biological fluids by HPLC. J Chromatogr 337:178–181Google Scholar
  10. 10.
    Statistical Consultants, Inc. (1986) PCNONLIN and NONLIN 84. Software for the statistical analysis of nonlinear models. Stat 40:52Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • D. J. Kerr
    • 1
  • J. A. Slack
    • 2
  • P. Secrett
    • 2
  • M. F. G. Stevens
    • 2
  • G. R. P. Blackledge
    • 3
  • C. Bradley
    • 1
  • S. B. Kaye
    • 1
  1. 1.CRC Department of Medical OncologyUniversity of GlasgowGlasgowU.K.
  2. 2.CRC Experimental Cancer Chemotherapy Research Group, Pharmaceutical Sciences InstituteAston UniversityBirminghamU.K.
  3. 3.West Midlands CRC Clinical Trials UnitQueen Elizabeth HospitalBirminghamU.K.

Personalised recommendations